Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA.
Neurology. 2010 Apr 13;74(15):1191-7. doi: 10.1212/WNL.0b013e3181d90050. Epub 2010 Mar 10.
To clinically characterize the temporal relationship between dyskinesia and the antiparkinsonian response when dyskinesia first emerges during long-term levodopa therapy and to determine if it is consistent with the hypothesized mechanism by which dyskinesia develops.
Dyskinesia and the antiparkinsonian response to levodopa during 2-hour levodopa infusions were monitored at intervals through the first 4 years of long-term levodopa therapy in 20 subjects with idiopathic Parkinson disease (PD) and previously untreated with levodopa. The onset and offset of the antiparkinsonian response and dyskinesia were compared when dyskinesia first appeared during the 4 years. The findings were compared to 20 subjects with PD on long-term levodopa with dyskinesia and motor fluctuations.
The onset and offset of the antiparkinsonian response and dyskinesia generally coincided when dyskinesia first appeared during the 4 years and did not suggest any temporal dissociation of the 2 responses. Further, the latency to the onsets of dyskinesia and the antiparkinsonian response tended to shorten during long-term levodopa therapy, suggesting that both responses were sensitized by long-term levodopa.
The similar onsets and offsets of the antiparkinsonian response and dyskinesia when dyskinesia first appears are not consistent with the postulated progressive decrease in threshold for dyskinesia during long-term levodopa therapy. Other mechanisms for the development of dyskinesia need to be considered.
在长期左旋多巴治疗中首次出现运动障碍时,临床描述运动障碍与抗帕金森反应之间的时间关系,并确定其是否与运动障碍发展的假设机制一致。
在 20 例特发性帕金森病(PD)患者的 4 年长期左旋多巴治疗期间,通过 2 小时左旋多巴输注每隔一段时间监测运动障碍和左旋多巴的抗帕金森反应,当运动障碍在 4 年内首次出现时比较抗帕金森反应和运动障碍的起始和消退。将这些发现与 20 例长期接受左旋多巴治疗且伴有运动障碍和运动波动的 PD 患者进行比较。
当运动障碍在 4 年内首次出现时,抗帕金森反应和运动障碍的起始和消退通常一致,这表明这两种反应没有时间上的分离。此外,运动障碍和抗帕金森反应的潜伏期在长期左旋多巴治疗期间趋于缩短,表明这两种反应均对长期左旋多巴敏感。
当运动障碍首次出现时,抗帕金森反应和运动障碍的起始和消退相似,这与长期左旋多巴治疗中运动障碍阈值逐渐降低的假设不一致。需要考虑运动障碍发展的其他机制。